Lung cancer is the commonest cancer diagnosis in both sexes. Half of these diagnoses are locally advanced or associated with distant metastasis. (2) Immunotherapy is now the first line treatment of choice for stage IV Non-Small Cell Lung Cancer (NSCLC) without driver mutations. (3) This article will review these agents combined with chemotherapy or as single agents, and the associated immune related autoimmune side effects (irAE) We will also explore treatment options following immunotherapy, including novel agents targeting KRAS G12C mutations. 2 cases will be used to illustrate these learning points.
For verified healthcare professionals
Log in or register for free to read this article. HPN is for healthcare professionals, so new accounts are verified by our team.
